FDA grants priority review to Genentech’s Enspryng for MOGAD
Reuters2026/09/10 05:11- FDA granted Priority Review for a supplemental BLA for Genentech’s Enspryng to treat MOGAD.
- Decision deadline set for Jan. 10, 2027; approval would make Enspryng the first disease-modifying therapy for MOGAD.
- Filing backed by Phase III METEOROID results showing a 68% relapse-risk reduction versus placebo.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
Goldman Sachs evaluates Apple's foldable iPhone: Pricing is “affordable,” with shipments this year reaching up to 35 million units
A Goldman Sachs report indicates that iPhone Duo, with its "thinnest ever" design and "affordable" pricing, is expected to open up the mass market. The forecast for 2026 remains at 14 to 35 million units shipped. The new product's upgrades in hinges, cooling, and camera technologies will benefit the supply chain in Greater China, including Foxconn.
Edyoutec partners with Skiply to sell 10Monkeys subscriptions in UAE from Sept. 15
Nissan reorganizes Japan manufacturing footprint, shifts vehicle production among plants
Crypto prices
More
